この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
ビジネス · 2020/9/291 分で読めます
Blood Glucose Monitoring Test Systems for Prescription Point-of-Care Use; Guidance for Industry and Food and Drug Administration Staff; Availability
ローカル自動翻訳 · 情報源の原言語
概要
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled "Blood Glucose Monitoring Test Systems for Prescription Point-of-Care Use." This guidance describes studies and information that FDA recommends be used when submitting premarket notifications (510(k)s) for blood glucose monitoring systems (BGMSs) that are for prescription point-of-care use.
情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →